Hot Features
Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Ovid Therapeutics Inc is a biopharmaceutical company. The firm is primarily engaged in developing impactful medicines for patients and families living who are suffering from epilepsies, seizure-related disorders, and neurological disorders. It is targeting disorders such as intellectual disability, ... Ovid Therapeutics Inc is a biopharmaceutical company. The firm is primarily engaged in developing impactful medicines for patients and families living who are suffering from epilepsies, seizure-related disorders, and neurological disorders. It is targeting disorders such as intellectual disability, severe speech impairment, problems with movement and balance, sleep disorders and anxiety to transform the patient's life. Mehr anzeigen
Two preclinical studies to be presented on OV329, a potential next-generation GABA aminotransferase inhibitor, highlighting its safety profile and lack of ocular accumulation relative to...
A Phase 1 SAD/MAD study of OV329 is progressing as planned, and based on encouraging human safety data to date, Ovid will engage regulators about adding cohorts to increase potential dosing...
NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain...
Study found OV329 cleared and remained undetectable in the retina, eye, and brain tissues of mice, unlike vigabatrin which has repeatedly shown to preferentially accumulate in mouse retinas, eyes...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.0309 | -3 | 1.03 | 1.09 | 0.9941 | 408046 | 1.02773915 | CS |
| 4 | -0.0409 | -3.93269230769 | 1.04 | 1.22 | 0.9941 | 257378 | 1.07615359 | CS |
| 12 | -0.1209 | -10.7946428571 | 1.12 | 1.47 | 0.9877 | 198185 | 1.13969403 | CS |
| 26 | 0.2381 | 31.2877792378 | 0.761 | 1.47 | 0.68 | 360381 | 0.94341049 | CS |
| 52 | -2.5209 | -71.6164772727 | 3.52 | 4.1 | 0.68 | 370871 | 1.40382261 | CS |
| 156 | -2.2109 | -68.8753894081 | 3.21 | 4.1389 | 0.68 | 227692 | 2.10323968 | CS |
| 260 | -3.3709 | -77.1372997712 | 4.37 | 10.45 | 0.68 | 641141 | 3.85084527 | CS |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
